Long-term effects of radioiodine treatment on salivary gland function in adult survivors of pediatric differentiated thyroid carcinomaDutch Pediat Thyroid Canc Study Co, Selvakumar, T., Nies, M., Hesselink, M. S. K., Brouwers, A. H., van der Horst-Schrivers, A. N. A., Hesselink, E. N. K., Tissing, W. J. E., Vissink, A. & Links, T. P., 1-Feb-2019, In : Journal of Nuclear Medicine. 60, 2, p. 172-177 6 p.
Research output: Contribution to journal › Article › Academic › peer-review
- Guided Treatment in Optimal Selected Cancer Patients (GUTS)
- Maintaining Oral Health and Oral Function (MOHOF)
- Translational Immunology Groningen (TRIGR)
- Damage and Repair in Cancer Development and Cancer Treatment (DARE)
- Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE)
Pediatric differentiated thyroid cancer (DTC) is a rare disease. Initial treatment of DTC consists of a (near) total thyroidectomy and radioactive iodine (131I) therapy. Previous studies in adults showed that 131I treatment may result in a reduced salivary gland function. Studies regarding salivary gland function in children treated for DTC are sparse. Our aim was to assess long-term effects of 131I treatment on salivary gland function in survivors of pediatric DTC. Methods: In a nationwide cross-sectional study, salivary gland function of patients treated for pediatric DTC between 1970 and 2013 (>5 years after diagnosis, ≥18 years old at time of evaluation) was studied. Salivary gland function was assessed by sialometry, sialochemistry and a xerostomia inventory. Salivary gland dysfunction was defined as unstimulated whole saliva flow ≤0.2mL/min and/or a stimulated whole saliva flow ≤0.7 mL/min. Results: Sixty-five patients (median age at evaluation 33 [IQR, 25-40] years, 86.2% female, median follow-up period 11 [IQR, 6-22] years) underwent 131I treatment. Median cumulative 131I activity was 5.88 [IQR, 2.92-12.95] GBq, 47.7% underwent multiple 131I administrations. Salivary gland dysfunction was present in 30 (47.6%) patients. Levels of amylase and total protein in saliva were reduced. Moderate to severe xerostomia was present in 22 (35.5%) patients. Stimulated salivary secretion was lower and severity of xerostomia complaints higher in patients treated with higher cumulative 131I activity. Conclusion: In survivors of pediatric DTC, clinically significant salivary gland dysfunction was found in 35.5% and was related to the cumulative 131I activity of the treatment.
|Number of pages||6|
|Journal||Journal of Nuclear Medicine|
|Early online date||30-Nov-2018|
|Publication status||Published - 1-Feb-2019|
- pediatric differentiated thyroid carcinoma, radioiodine treatment, salivary gland dysfunction, xerostomia, RADIOACTIVE IODINE THERAPY, QUALITY-OF-LIFE, I-131 THERAPY, CANCER, SIALADENITIS, XEROSTOMIA, RISK, INTERMEDIATE, FERTILITY, FLOW